Medical Devices - Diagnostic Imaging and Endomicroscopy
Strategic Profile
The company has obtained regulatory approvals to commercialize its Cellvizio system in Switzerland and the United Kingdom, providing access to strategic European markets recognized for excellence in interventional gastroenterology. Recent organizational changes announced in February 2026 aim to accelerate growth outside the United States by structuring international expansion of both Cellvizio and CellTolerance programs.
Cyborg Score Rationale
The company experienced what CEO described as perhaps the most challenging period in Mauna Kea's history in 2024. However, the Paris Commercial Court approved its safeguard plan in November 2025, ending safeguard proceedings initiated March 2025. Recent regulatory approvals and strategic partnerships demonstrate recovery momentum.
Top Insights
The company secured firm subscription commitments exceeding €5 million following court approval of its safeguard plan in November 2025.
Mauna Kea announced an exclusive U.S. partnership with TaeWoong Medical for pancreatic cyst management, creating an integrated imaging-to-therapy solution designed to enhance clinical accuracy and patient outcomes.
The company received CE MDR certification for its entire Cellvizio system and probe range from GMED, a leading notified body in the medical device sector.
Mauna Kea is pursuing exclusive licensing negotiations for Cellvizio in an important therapeutic area with a major industry player and discussing licenses covering other therapeutic areas.
Named Competitors
Endoscopic Imaging Systems — Competitor in endoscopic imaging and visualization
Advanced Diagnostic Imaging — Competitor in minimally invasive endoscopic solutions
Optical Biopsy Solutions — Competitor in medical imaging devices
Recent Developments
(February 2026) Obtained regulatory clearances in Switzerland and the United Kingdom; announced new organizational structure to accelerate international expansion
(December 2025) Signed exclusive U.S. partnership with TaeWoong Medical for pancreatic cyst management solution
(November 2025) Exited safeguard proceedings following court approval of restructuring plan; secured €5M+ capital raise
(April 2025) Announced entry into exclusive licensing negotiations for Cellvizio with major industry player
Open the full interactive Mauna Kea Technologies report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.